Navigation Links
Delcath Enters Agreement to Sell 869,565 Units
Date:6/10/2009

final prospectus supplement and accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or from Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
2. Jonathan Lewis, M.D., Ph.D. Steps Down From Delcath Systems Board of Directors
3. Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors
4. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
5. Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma
6. Delcath Systems Granted Third Orphan Drug Designation
7. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
8. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
9. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
10. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
11. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... interface is the device," Nobel laureate Herbert Kroemer ... be found at the junctures where layers of ... nanotechnology, the interfaces between layers of metal oxides ... high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics and ...
(Date:1/15/2014)... Look inside the new Preferred Solutions® catalog ... from fluid handling to instruments to supplies. Many items ... order. , Preferred Solutions features a full selection ... model for precise flow control and dispensing to I/P® ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... , a biotechnology company focused on the development and ... has entered into an in-vitro diagnostics patent license agreement ... , ,Under the agreement, which will be effective July ... in its products. Prodesse also receives the authority to ...
... monthly column, "Buzz Networks," will provide insights, descriptions, analysis, ... and concepts that are gaining credibility and providing utility ... deeply into the underlying technology, but rather will focus ... platforms. We look forward to your feedback and participation ...
... Wis. - It's not often that a tax is ... consumers start popping champagne corks over the recent elimination of ... know that getting some of their money back will require ... United States Treasury ruling has effectively eliminated the ...
Cached Biology Technology:Social computing in the Web 2.0 era 2Social computing in the Web 2.0 era 3Social computing in the Web 2.0 era 4Social computing in the Web 2.0 era 5Elimination of phone tax tempered by paperwork 2Elimination of phone tax tempered by paperwork 3
(Date:4/23/2014)... technique used to read quickly. It involves visual ... words and/ or sentences. Similarly to humans, biological ... "read" genetic information. Genes that need to be ... the encoding message, the easier it will be ... Gulbenkian de Cincia (IGC, Portugal) and Centre for ...
(Date:4/22/2014)... -- There are all sorts of signaling strategies in ... colorful tails; satin bowbirds build specialized stick structures, called ... and European bitterling males show off bright nuptial coloration ... method to communicate with others. , ... have profound fitness implications for individuals that are either ...
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
Breaking Biology News(10 mins):Cell division speed influences gene architecture 2Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... such, they are relatively well studied, especially in the ... most thoroughly. First eastern US butterfly species were described ... himself, over 250 years ago. For the last ... species diversity of eastern butterflies, and every nook and ...
... A*STAR,s Institute of Molecular and Cell Biology (IMCB) have ... the pathway leading to memory and learning impairment. The ... and could be used to explain defects in the ... established knowledge could potentially facilitate exploration of strategies to ...
... plant that,s been known to drive people daffy. It,s one ... a hard-to-control weed in ponds and small lakes. But it,s ... source to produce pharmaceuticals. Now, the genome of Greater Duckweed ... as a biofuel source a big boost. In a paper ...
Cached Biology News:Two new butterfly species discovered in eastern USA 2A*STAR scientists discover protein's role in human memory and learning functions 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
AANAT [Arylalkylamine N-acetyltransferase; EC 2.3.1.87]...
TUP1 Market Segment: Molecular Biology...
NANS Immunogen: NANS (NP_061819, 260 a.a. ~ 360 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: